PMID- 26104380
OWN - NLM
STAT- MEDLINE
DCOM- 20160805
LR  - 20181202
IS  - 1096-9071 (Electronic)
IS  - 0146-6615 (Linking)
VI  - 88
IP  - 1
DP  - 2016 Jan
TI  - The role of DCs in the immunopathogenesis of chronic HBV infection and the 
      methods of inducing DCs maturation.
PG  - 13-20
LID - 10.1002/jmv.24306 [doi]
AB  - Chronic hepatitis B virus (HBV) infection is the result of an inadequate immune 
      response towards the virus. Dendritic cells (DCs), as the most efficient 
      professional antigen-presenting cells (APCs), possess the strongest antigen 
      presenting the effect in the body and can stimulate the initial T cell activation 
      and proliferation. DCs of patients with chronic HBV infection are impaired, 
      resulting in more tolerogenic rather than immunogenic responses, which may 
      contribute to viral persistence. Recently, numerous methods have been developed 
      to induce DCs maturation. To date, recombinant human granulocyte-macrophage 
      colony stimulating factor (rhGM-CSF) combined with interleukin-4 (rhIL-4) has 
      been a classic culture combination to DCs. The recently classified type III 
      interferon group interferon-lambda (IFN-lambda) displays antiviral, antitumor, and 
      immunoregulatory activity. In our laboratory, we demonstrate that IFN-lambda1 combined 
      with rhGM-CSF and rhIL-4 can significantly increase the expression of DC surface 
      molecules and the secretion of interleukin-12 (IL-12) and interferon-gamma (IFN-gamma) in 
      patients with chronic hepatitis B infection. In this review, we emphasize on the 
      role of DCs in the immunopathogenesis of chronic HBV infection. Importantly, we 
      systematic review that the latest update in the current status of knowledge on 
      the methods of inducing DCs maturation in anti-HBV immunity. What's more, we 
      conclude that IFN-lambda1 combined with GM-CSF and IL-4 can induce DCs maturation, 
      which could become a possibility to be applied to the autologus dendritic cell 
      vaccine to treat chronic hepatitis B.
CI  - (c) 2015 Wiley Periodicals, Inc.
FAU - Sun, Hai-Hua
AU  - Sun HH
AD  - Department of Infectious Disease, Third Hospital, Hebei Medical University, 
      Shijiazhuang, China.
FAU - Zhou, Dong-Fang
AU  - Zhou DF
AD  - Department of Infectious Disease, Third Hospital, Hebei Medical University, 
      Shijiazhuang, China.
FAU - Zhou, Jun-Ying
AU  - Zhou JY
AD  - Department of Infectious Disease, Third Hospital, Hebei Medical University, 
      Shijiazhuang, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20150716
PL  - United States
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Dendritic Cells/*immunology
MH  - Hepatitis B virus/*immunology/*physiology
MH  - Hepatitis B, Chronic/*immunology/*pathology/therapy
MH  - Host-Pathogen Interactions
MH  - Humans
MH  - *Immune Tolerance
MH  - Immunologic Factors/therapeutic use
OTO - NOTNLM
OT  - DCs maturation
OT  - autologus dendritic cell vaccine
OT  - dendritic cells
OT  - hepatitis B virus
OT  - interferon-lambda
EDAT- 2015/06/25 06:00
MHDA- 2016/08/06 06:00
CRDT- 2015/06/25 06:00
PHST- 2015/06/11 00:00 [accepted]
PHST- 2015/06/25 06:00 [entrez]
PHST- 2015/06/25 06:00 [pubmed]
PHST- 2016/08/06 06:00 [medline]
AID - 10.1002/jmv.24306 [doi]
PST - ppublish
SO  - J Med Virol. 2016 Jan;88(1):13-20. doi: 10.1002/jmv.24306. Epub 2015 Jul 16.